Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells

Reproductive Sciences

Volumn 20, Issue 12, 2013, Pages 1433-1446

  Erices, Rafaela ^a,b,c   Bravo, Maria Loreto ^a,c   Gonzalez, Pamela ^a,c   Oliva, Bárbara ^a,c   Racordon, Dusan ^a   Garrido, Marcelo ^a   Ibañez, Carolina ^a   Kato, Sumie ^d   Brañes, Jorge ^d   Pizarro, Javier ^e   Barriga, Maria Isabel ^e   Barra, Alejandro ^f   Bravo, Erasmo ^g   Alonso, Catalina ^g   Bustamente, Eva ^h   Cuello, Mauricio A ^d   Owen, Gareth I ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c Biomedical Research Consortium of Chile   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^f HOSPITAL BARROS LUCO TRUDEAU   (Chile)

^g Hospital Dr Gustavo Fricke   (Chile)

^h Instituto Oncológico Fundación Arturo López Pérez   (Chile)

Author keywords

chemotherapy; doxorubicin; paclitaxel

Indexed keywords

CARBOPLATIN; DOXORUBICIN; METFORMIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL;

CHEMOTHERAPY; DOXORUBICIN; PACLITAXEL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVARIAN NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 84887496514     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113488441     Document Type: Article

References (37)

1. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009 ; 9 (6). 415-428
2. Green AE, Rose PG. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine. 2006 ; 1 (3). 229-239
3. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 ; 19 (14). 3312-3322 (Pubitemid 32642183)
4. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010 ; 33 (2). 322-326
5. Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009 ; 55 (4). 363-369
6. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 1995 ; 49 (5). 721-749
7. Binnert C, Seematter G, Tappy L, Giusti V. Effect of metformin on insulin sensitivity and insulin secretion in female obese patients with normal glucose tolerance. Diabetes Metab. 2003 ; 29 (2 pt 1). 125-132 (Pubitemid 36576090)
8. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig. 2011 ; 31 (6). 435-438
9. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 ; 330 (7503). 1304-1305 (Pubitemid 40813563)
10. Li D. Metformin as an Antitumor Agent in Cancer Prevention and Treatment. J Diabetes. 2011 ; 3 (4). 320-327
11. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009 ; 69 (19). 7507-7511
12. Song CW, Lee H, Dings RP, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012 ; 2: 362
13. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011 ; 121 (3). 492-498
14. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011 ; 15 (1). 166-178
15. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011 ; 13 (5). 483-491
16. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc. 2006 ; 1 (6). 2643-2649
17. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 1987 ; 47 (2). 414-418 (Pubitemid 17009602)
18. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 2001 ; 81 (3). 380-390 (Pubitemid 32494651)
19. Li HZ, Wang Y, Gao Y, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res. 2008 ; 6 (6). 917-928
20. Kato S, Sadarangani A, Lange S, et al. The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium. Endocr Relat Cancer. 2007 ; 14 (2). 351-368 (Pubitemid 47242635)
21. Sadarangani A, Kato S, Espinoza N, et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis. 2007 ; 12 (1). 73-85 (Pubitemid 46009505)
22. Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010 ; 70 (4). 1616-1624
23. Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 2008 ; 7 (3). 630-637 (Pubitemid 351482145)
24. Hunz M, Jetter A, Warm M, et al. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther. 2007 ; 81 (5). 659-668 (Pubitemid 46625101)
25. Nagai N, Kinoshita M, Ogata H, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol. 1996 ; 39 (1-2). 131-137 (Pubitemid 26400671)
26. Celio LA, DiGregorio GJ, Ruch E, Pace J, Piraino AJ. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol. 1983 ; 24 (2). 261-266 (Pubitemid 13147723)
27. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 ; 119 (1). 61-67
28. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012 ; 18 (10). 2905-2912
29. Xiong X, Sui M, Fan W, Kraft AS.. Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther. 2007 ; 6 (7). 1067-1073 (Pubitemid 351574958)
30. Davis AJ, Chapman W, Hedley DW, Oza AM, Tannock IF. Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytometry A. 2003 ; 51 (1). 1-6 (Pubitemid 37517305)
31. Benepal T, Jackman A, Pyle L, et al. A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. Br J Cancer. 2005 ; 93 (8). 868-875 (Pubitemid 41487011)
32. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1987 ; 7 (11). 1748-1756 (Pubitemid 19272848)
33. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011 ; 9: 33
34. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2011 ; 29 (2). 1314-1327
35. Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011 ; 119 (2). 63-68
36. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011 ; 71 (13). 4366-4372
37. Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol. 2011 ; 6 (11). 1784-1792